Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Conditional approval would permit marketing while additional effectiveness data are collected, subject to annual FDA renewal.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Endovia Health Sciences (EDVA) and Lupvindol BioSciences announced an FDA minor-use determination making CannEpil eligible to pursue conditional approval for canine bone-cancer pain. The investigational CBD and THC oral solution will retain minor-use status through approval of the applicable New Animal Drug Application. Conditional approval requires safety and manufacturing standards and a reasonable expectation of effectiveness, with additional effectiveness data collected afterward for full approval.
The companies will meet with the FDA on November 19, 2026 to discuss studies, manufacturing requirements and regulatory submissions. They are sourcing and finalizing U.S. manufacturing capabilities. Endovia anticipates a potential 2027 veterinary launch, subject to FDA review, regulatory requirements and manufacturing readiness. CannEpil has not received FDA approval or conditional approval.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA minor-use determination establishes CannEpil’s eligibility to pursue conditional approval for canine bone-cancer pain.
- Moderate pointU.S. manufacturing capabilities are being sourced and finalized to support development and potential commercialization.
- Minor point. Forward-looking: it has not happened yet and may not happen.Minor-use status will be maintained through approval of the applicable New Animal Drug Application.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential 2027 veterinary launch is part of Endovia’s anticipated development timeline.
Negative
- Minor pointConditional approval requirements include safety and manufacturing standards and a reasonable expectation of effectiveness.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential launch remains dependent on FDA review, completion of regulatory requirements and manufacturing readiness.
- Minor point. Forward-looking: it has not happened yet and may not happen.Annual FDA renewal is required following conditional approval while additional effectiveness data support full approval.
News Explained
Following conditional approval, the pathway would allow CannEpil to be marketed while further effectiveness data are collected for full approval; conditional approval is subject to annual FDA renewal.
Details
Market move: EDVA +4.96% vs previous close. FDA minor-use determination
On Oct 5, the day this news came out, the latest delayed price for EDVA is 4.96% above the previous close. Our momentum scanner has recorded 19 alerts for this stock so far that day. The latest delayed price is $0.17. Relative volume is exceptionally heavy at 306.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Pre-submission conference
- November 19, 2026
- Scheduled FDA meeting on the proposed CannEpil development program
- Potential veterinary launch
- 2027
- Subject to regulatory approvals and manufacturing readiness
Historical Context
-
Company planned CannEpil FDA submission and sought a pre-submission conference.
-
FDA opened CannEpil's INAD file as Endovia planned to pursue MUMS conditional approval.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cbd medical
tetrahydrocannabinol medical
new animal drug application regulatory
investigational new animal drug regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product Launch
FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration’s (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.
The FDA determination establishes CannEpil’s eligibility to pursue the conditional approval pathway for this proposed indication. The FDA further determined that the minor-use status will be maintained through approval of the applicable New Animal Drug Application (“NADA”).
Under the MUMS framework, qualifying new animal drugs may be eligible for conditional approval which is a regulatory pathway designed to facilitate earlier availability of therapies for uncommon diseases and conditions in animals. Conditional approval requires satisfaction of applicable FDA requirements, including safety and manufacturing standards and a reasonable expectation of effectiveness, while allowing additional effectiveness data required for full approval to be collected following conditional approval.
Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, for a Pre-Submission Conference to discuss and align with the FDA on the proposed CannEpil® development program, including the studies, manufacturing requirements and regulatory submissions necessary to pursue conditional approval.
In parallel with the regulatory program, Endovia and Lupvindol are actively sourcing and finalizing U.S.-based manufacturing capabilities for CannEpil®. This work is intended to establish a scalable, FDA-compliant domestic supply chain capable of supporting the clinical and regulatory program and, subject to receipt of the necessary regulatory approvals, a potential commercial launch for veterinary use in 2027.
“This determination represents an important regulatory milestone for CannEpil® and provides greater clarity around the pathway we are pursuing with the FDA,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “Importantly, we are not waiting to begin preparing for commercialization. Alongside Lupvindol, we are advancing our FDA development program while simultaneously working to establish U.S. manufacturing and supply capabilities that can support a potential veterinary launch in 2027, subject to regulatory approval.”
Cobb continued, “We believe CannEpil has the potential to demonstrate what a science-driven, federally regulated cannabinoid medicine can look like in the United States. Our veterinary program gives us an opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing and scientific infrastructure that we believe can support the broader development of CannEpil.”
The MUMS conditional approval pathway was established to encourage development of new animal drugs for uncommon conditions affecting relatively small populations. Following conditional approval, a sponsor may legally market a qualifying animal drug while continuing to collect the additional effectiveness data necessary to support full FDA approval, subject to applicable statutory and regulatory requirements and annual FDA renewal.
CannEpil® remains an investigational new animal drug and has not been approved or conditionally approved by the FDA. The Company’s anticipated development timelines, including a potential 2027 commercial launch, remain subject to FDA review, successful completion of applicable regulatory requirements, manufacturing readiness and other factors.
About CannEpil®
CannEpil® is a proprietary cannabinoid-based oral formulation containing cannabidiol (CBD) and tetrahydrocannabinol (THC). Endovia and Lupvindol BioSciences are advancing CannEpil through the FDA’s Center for Veterinary Medicine for the proposed control of pain associated with bone cancer in dogs.
The veterinary development program is part of Endovia’s broader strategy to develop cannabinoid-based therapeutics through established federal regulatory pathways and to build a platform capable of supporting additional veterinary and human therapeutic applications, subject to applicable statutory and regulatory requirements.
About Endovia Health Sciences
Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.
About Lupvindol Biosciences Ltd.
Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose experience includes participation in the development of Epidiolex® and Sativex® at GW Pharmaceuticals.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform act of 1995 including statements regarding the development and commercialization of CannEpil®; obtaining a manufacturing source, and a potential commercial veterinary launch in 2027.
Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Some or all of these risks may not occur. These risks include the Company’s ability to obtain additional financing; the development of and obtaining regulatory authorization for and commercialize CannEpil® for veterinary use, the results of any clinical trials, the availability of raw materials, the ability to obtain a manufacturer to meet our needs on a financially viable basis, ; maintaining its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; ability to meet competition from both CBD and conventional pharmaceuticals products ,our ability to successfully execute commercialization or strategic-partnering arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected.
Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.
Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contact
Endovia Health Sciences
investors@endoviasciences.com
Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the FDA minor-use determination mean for Endovia’s CannEpil?
The determination makes CannEpil eligible to pursue conditional approval for control of pain associated with bone cancer in dogs. Minor-use status will be maintained through approval of the applicable New Animal Drug Application. The determination is not FDA approval or conditional approval.
When could Endovia launch CannEpil for veterinary use?
Endovia anticipates a potential commercial launch in 2027, subject to FDA review, completion of applicable regulatory requirements and manufacturing readiness. Endovia and Lupvindol are sourcing and finalizing U.S.-based manufacturing capabilities to support the development program and potential launch.
Can Endovia market CannEpil after conditional approval while pursuing full approval?
Following conditional approval, a sponsor may legally market a qualifying animal drug while collecting the additional effectiveness data needed for full FDA approval. This remains subject to applicable statutory and regulatory requirements and annual FDA renewal.